NEU NEUCA S.A.
NEUCA S.A. engages in the wholesale distribution of pharmaceuticals in Poland. It operates through Wholesale Distribution of Medicines, Manufacture of Pharmaceuticals, Medical Operator, Clinical Trials, and Insurance Activities segments. The company offers Rx, OTC drugs, dietary supplements, medical devices, dermocosmetics, hygiene products, personal protective equipment, as well as diagnostic and dressing materials under the Swiat Zdrowia, APTEO, GENOPTIM, CERA+ Solutions, and Kic Kic brands. It also provides medical care services, including prevention, diagnostics, treatment, and complementary services; and financing services, such as insurance, subscriptions, occupational medicine, preventive and medicine programmes, FFS, NFZ, public, private, and corporate payer services. In addition, the company offers TPA services, remote consultations, in person visits, diagnostic tests, and occupational medicine services; operates a medical helpline and medical facilities; and offers medicine through apteline.pl, an e-commerce medical ordering site. Further, it engages in running clinical trials in the field of outsourcing clinical research and conducting clinical research centres; provision of insurance products, including health insurance products. Additionally, the company provides advertising and marketing services to pharmaceutical market entities; and logistics services for pharmaceutical manufacturers. The company was formerly known as Torfarm SA and changed its name to NEUCA S.A. in April 2010. NEUCA S.A. was founded in 1990 and is based in Torun, Poland.…
Industry Peers
Medical DistributionKey Statistics
About NEUCA (WSE: NEU)
›
NEUCA (WSE: NEU) is listed on Warsaw Stock Exchange, where its shares trade in PLN. It belongs to the Medical Distribution industry, part of the Healthcare sector, and reports about 5,004 employees.
The shares were at 722.00 PLN on 20 November 2026, up 10.2% over 52 weeks. Its 52-week range is 645.00 PLN to 857.00 PLN: the price is 15.8% below the high and 11.9% above the low.
At a market capitalisation of 3.27B PLN, it trades at 16.7 times trailing earnings and 13.2 times forward earnings. The median trailing P/E of its 17 largest Medical Distribution peers is 22.9, a discount of 27% for NEU. It pays a dividend yielding 2.49% (it pays out 42% of its earnings), against a median of 1.38% among the dividend payers in that peer group.
NEUCA reports return on equity of 14.7%, an operating margin of 2.1% and revenue up 5.5% year over year.
Its debt exceeds its cash by 538.82M PLN, a debt-to-equity ratio of 0.47. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 5 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 951.44 PLN is 31.8% above the current price.